Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.
Introduction
Chronic myeloid leukemia (CML) is a well-known hematological malignancy that is characterized in most patients by the translocation t (9; 22) (q34; q11), leading to the formation of the Philadelphia chromosome carrying the chimeric oncogene breakpoint cluster region-Abelson (BCR-ABL). The slow progression of CML can be stopped if the disease is diagnosed and managed early enough with the reference treatment, imatinib, a first-generation tyrosine kinase inhibitor (TKI). Imatinib acts to block the BCR-ABL protein, which has constitutive tyrosine kinase activity, in its inactive form. However, resistances to imatinib and the second and third generation TKIs frequently develop in patients, leading researchers to synthesize molecules targeting other proteins involved in this pathology, such as histone deacetylase 6 (HDAC6). In this review, we will discuss the characteristics and implication of the HDAC6 protein in CML.
Chronic Myeloid Leukemia
CML is a myeloproliferative disorder affecting myeloid progenitors and is considered as a rare cancer with an incidence of approximately 1 in 100000 cases each year in Europe and the United States [1, 2] . There are an estimated 6370 new cases each year in Europe [3] and 8430 new cases have been reported in 2018 in the United States [2] . CML is characterized by an excessive proliferation of leukocytes in the bone marrow, most of which are still immature, and called blasts when they pass into the blood [4] . This pathology comprises three distinct phases: the chronic, accelerated, and blast phases [5] (Figure 1 ). Figure 1 . Progression of chronic myeloid leukemia. Chronic myeloid leukemia (CML) is characterized by an excessive proliferation of non-functional leukocytes (dotted lines) or blasts in the bone marrow and then in the blood. The chronic phase remains generally asymptomatic, during which 5% blasts are found in the bloodstream. After 5 to 6 years without treatment, the pathology progresses towards the accelerated phase (5% to 20% blasts) and symptoms including fatigue and loss of appetite and weight begin to appear. Without treatment, the accelerated phase progresses in 6 to 9 months to the blast phase (more than 20% blasts), causing rapid deterioration of the general condition of the patient and death after only a few months without management. Symptoms and resistance to therapy increase during the course of chronic myeloid leukemia, while the probability of survival decreases.
Chromosomal Rearrangement during Chronic Myeloid Leukemia
A chromosomal anomaly, the t (9; 22) (q34; q11) translocation between chromosome 9, which carries the ABL gene, and chromosome 22, which carries the BCR gene, is found in 95% of patients with CML. This translocation leads to the formation of the Philadelphia chromosome carrying the BCR-ABL chimeric gene (Figure 2A) , and thus to the expression of the corresponding fusion oncoprotein, which has a constitutive tyrosine kinase activity. The Philadelphia or Ph + chromosome was identified for the first time in 1960 by the researchers Hungerford and Nowell in the city of Philadelphia, for which it was named [6, 7] .
BCR-ABL mRNA and Protein
There are multiple breakpoints on the BCR and ABL genes that lead to the formation of different transcripts ( Figure 2B ). These transcripts encode BCR-ABL proteins of different sizes that have been found in patients (Table 1 ) [4] . The hybrid mRNA eXaY is produced after cleavage occurs after exon X of BCR and before exon Y of ABL; (C) ABL protein (145 kDa) has tyrosine kinase activity and predominantly nuclear localization. It comprises a long lipid chain, myristate (Myr), conferring a capacity for self-inhibition, SH2 and SH3 domains of Src homology, allowing interactions with proline-rich regions and with phosphorylated tyrosines, respectively, a tyrosine kinase (TK) domain, and finally an actin-binding domain (ABD) binding domain to DNA and β-actin. ABL is involved in cytoskeletal dynamics (adhesion, polarity, cell migration, and cellular protrusions), proliferation and cell survival, membrane transport (endocytosis, macropinocytosis, phagocytosis, and caveolae formation) by phosphorylating receptors such as epidermal growth factor receptor, platelet-derived growth factor beta receptor and muscle specific tyrosine kinase receptor [8] , and finally in autophagy [9, 10] . ABL protein is involved in neurodegenerative diseases and neuroinflammation [9, 10] . The BCR protein (160 kDa) has serine/threonine kinase activity and is localized in the cytoplasm [11] . BCR comprises an oligomerization domain (OLI). Mutations in this domain cause a decrease in the tyrosine kinase activity of the BCR-ABL protein and prevent the interaction of BCR and BCR-ABL proteins. It also has a domain of homology to the protein DBL [guanosine diphosphate exchange factor (GDP) in guanosine triphosphate (GTP)], a domain of pleckstrin homology (PH), a C2 domain for binding of calcium-dependent phospholipids, and finally a GTPase (GTPase activating protein) domain (GTPase hydrolysis in GDP and phosphate ion) for binding to Rac proteins. Table 1 . Human BCR-ABL transcripts and proteins. The name and composition of the various human BCR-ABL hybrid transcripts identified in patients are described. The size of the corresponding proteins, their frequency of detection, and the cell lines expressing them are also indicated. The BCR-ABL protein activates many substrates ( Table 2 ) and signaling pathways, including some involved in cell proliferation and survival, through increased activity or expression of a series of anti-apoptotic proteins including the signal transducer and transcriptional activator 5 (STAT5), Akt, phosphoinositide 3-kinase, or B-cell lymphoma-extra-large [20] . 
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CML Treatments and Associated Resistance Mechanisms
Targeted Therapy with a Tyrosine Kinase Inhibitor
In the 1960s, CML was treated with chemotherapy using busulfan and hydroxyurea. Two different therapeutic strategies emerged in the 1970s: allogeneic stem cell transplantation and the use of interferon- [5] . A new therapy was approved in 2001 by the Food and Drug Administration (FDA) using the TKI imatinib (Gleevec®) [50] . TKIs represent a major advance in the management of CML patients by enabling targeted therapy for the first time.
There are two types of TKIs: type I TKIs target the active and inactive conformation of the BCR-ABL protein and bind to the ATP binding site on the tyrosine kinase domain of the protein, whereas type II inhibitors target the inactive conformation of the protein and bind to a site adjacent to the available ATP binding site when the activation loop is not phosphorylated [51, 52] .
Imatinib is a type II TKI. Its action therefore prevents the binding of ATP, and thus blocks the protein in its inactive form, preventing its autophosphorylation, and therefore preventing the phosphorylation of its substrates [53] . Imatinib is the first-line treatment for CML with daily oral intake. According to the IRIS study, including 1106 new patients with CML, 76% of patients treated with imatinib also lost the Philadelphia chromosome, also called a complete cytogenetic response. This treatment with a TKI thus allowed stabilization of the pathology in the chronic phase, allowing patients to live normally. However, this treatment has numerous side effects including fatigue, headaches, anemia and myalgia, which are more common, and sometimes even leading to organ toxicity in the liver or heart, which can cause QT interval prolongation associated with a high risk of rhythm disturbances and serious ventricular disease, which are uncommon and occur in less than 1% of patients treated with imatinib [5] .
Patients treated with imatinib should be closely monitored to assess their response to treatment. There are three types of responses: the hematological, cytogenetic, and molecular responses. A complete hematologic response corresponds to normalization of blood levels and spleen size. An examination is performed every two weeks until a complete hematologic response is obtained, followed by a control every three months. Then, an examination is performed every 6 months until reaching a complete cytogenetic response, then every 12 to 18 months. Finally, a complete molecular response corresponds to the total disappearance of the BCR-ABL transcript, which is measured by reverse transcription followed by real-time PCR amplification. This test is performed every 3 months according to the recommendations of the European leukemia net [54] .
Imatinib Resistances
Although imatinib is the gold standard for CML treatment, 35% to 40% of patients develop resistances to this drug [55] . It is possible to distinguish between primary resistances, defined as a complete lack of hematological response after 3 months, cytogenetic response after 6 months, or a major cytogenetic response after one year of treatment; and secondary resistances, also called acquired resistances, when the previous hematologic or cytological response is lost. Resistances can also be classified according to whether or not they depend on BCR-ABL [56, 57] . The emergence of resistances has led to the development of new TKIs (Table 3 ). [58, 59] ° Type II inhibitor binding to the inactive conformation of BCR-ABL. * Type I inhibitor binding to the active and inactive conformation of BCR-ABL. BCR-ABL: breakpoint cluster region-Abelson; FTL3: Fms-like tyrosine kinase 3; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection.
BCR-ABL-Dependent Resistance Mechanisms
BCR-ABL-dependent resistance can be caused by duplication and mutation of the BCR-ABL gene ( Figure 3 ). Duplication of the gene has been identified in the cells of imatinib-resistant patients and could be a possible source of drug resistance [63] . Although overexpression of BCR-ABL has been reported in patients with accelerated and blastic phase CML who became resistant to imatinib, several studies have shown that only 3% of imatinib-resistant patients have amplification of BCR-ABL gene [64] .
Mutations in BCR-ABL are more common than duplications and occur in 40% to 90% of imatinib-resistant patients, depending on the sensitivity of the detection method used and the stage of CML [65] . To date, more than a hundred have been discovered [66] , which can explain the recently observed decrease in the effectiveness of imatinib treatment [63] . The first mutation described, which is also the most common, represents 14% of all mutations detected [64] , and corresponds to the nucleotide substitution of a cytosine by a thymine at position 944 of the ABL gene. This mutation results in the substitution of the amino acid 315, initially threonine, with an isoleucine (T315I). This results in the loss of an oxygen molecule that is necessary for the hydrogen bond between imatinib and the tyrosine kinase domain, and also creates steric hindrance, preventing binding and drastically reducing treatment efficacy [67] [68] [69] . Figure 3 . BCR-ABL-dependent and -independent imatinib resistances. BCR-ABL-dependent (purple) and -independent (blue) resistances can be explained by BCR-ABL duplication and mutation mechanisms, co-medication, interindividual variety, decreased import proteins, increased export proteins, binding of imatinib to plasma proteins, and the presence of imatinib-insensitive leukemic stem cells (LSCs). CYP3A4: cytochrome 3A4.
The seven most common mutations are: G250A/E, Y253F/H, and E255D/K/R/V located in the ATP binding P-loop, T315I located at the imatinib binding site, M351T and F359C/L/V/R located in the catalytic loop, and H396P located at the activation loop A [64] . Mutations at the P-loop represent 38% to 46% of all mutations and result in a conformational change that prevents imatinib from binding to BCR-ABL [54] . Mutations occurring at loop A prevent BCR-ABL from attaining its active conformation, thus also preventing binding to imatinib [64] .
It is interesting to note that the frequency of mutations is higher in patients who have developed secondary resistance, and that the site of mutation varies according to the progression of the pathology. Mutations of amino acids at position 244, 250, and 351 are more frequent in patients in the chronic phase, whereas mutations of amino acids at position 253, 255, and 315 are more frequently encountered in patients in the accelerated or blast phases [64] .
BCR-ABL-Independent Resistance Mechanisms
BCR-ABL-independent resistances can be explained by interindividual variability, increased export protein, decreased import protein, and also by binding of imatinib to plasma proteins [67] .
Interindividual variability may underlie differences in drug metabolism, and thus a different drug response in patients. The metabolization of imatinib to its main circulating metabolite, the N-desmethyl piperazine derivative [55] , progresses via cytochrome (CYP) P450, and in particular to the CYP3A4 isoform, which has variable activity. This may explain the observed lower levels of imatinib in some patients despite a similar dose. Cytochrome CYP3A4 can be activated or inhibited by many drugs. The metabolization of imatinib by CYP3A4 may therefore be important during co-medication [65] .
A reduced cellular concentration of imatinib can be explained by decreased levels of import proteins or by increased levels of export proteins ( Figure 3B ). The organic cation transporter (OCT)1 is responsible for the influx of imatinib into leukemic cells, and a polymorphism of this transporter is associated with imatinib resistance in K-562 CML cells [64] . Glycoprotein P, also known as multi-drug resistance protein 1, is an export protein that has been associated with failed leukemia treatment by chemotherapy. Recent studies have supported the notion that imatinib is also a substrate for glycoprotein P [70] .
Although this hypothesis remains controversial in the literature, the binding of imatinib to plasma proteins such as alpha-1-acid glycoprotein may explain the decrease in free imatinib concentration described in some patients with little or no response to treatment [54, 64] .
Finally, the existence of quiescent leukemic stem cells (LSC), which are unaffected by current drug therapies, would also explain the emergence of resistance to imatinib. LSCs are derived from a group of myeloid progenitors that gain the ability to self-renew, become quiescent, and finally survive in specific microenvironments called hematopoietic niches [4] . These allow interactions between the LSCs and the cells of the microenvironment, which can promote the development of resistance mechanisms. The persistence of LSCs in the presence of TKIs could be the cause of the molecular minimal residual disease that can promote the long-term development of resistance, making them potentially responsible for the clonal evolution and progression of CML [71] .
Development of Novel Tyrosine Kinase Inhibitors
The emergence of resistances to imatinib has led to the development of new TKIs with an activity against specific mutations in BCR-ABL protein. Dasatinib and nilotinib are second-generation TKIs (Table 3 ) used in cases of imatinib resistance, allowing a complete, lasting cytogenetic response in approximately 40% of these cases. Despite promising results, these new molecules are nevertheless not effective in patients with the T315I mutation, and lead to the appearance of new mutations generating resistance and subsequently to a decrease in their effectiveness. In addition, the benefit-risk ratio is important to consider as the side effects caused by second-generation TKIs are numerous, and for the most part similar to those generated by imatinib [5] .
Ponatinib is a third generation TKI (Table 3 ) that are effective in second generation TKI refractory patients [72] . Only ponatinib is effective in patients with imatinib resistance associated with the T315I mutation. A complete cytogenetic response was observed in 46% of chronic phase patients receiving ponatinib who had already been treated with other TKIs. Data from a phase II study suggest an increased incidence of arterial thrombotic events in patients receiving ponatinib, thus ending a phase III study. In addition, third generation TKIs do not escape the appearance of resistance phenomena [5, 62] . Third generation TKIs also include radotinib, a TKI with structural similarities to imatinib and nilotinib, which was approved in Korea in 2012 for the second-line treatment of CML [73] . This TKI is one of the most effective treatments for chronic phase CML [74] but has side effects including pigment changes such as eruptive melanocytic nevi [75] .
Histone Deacetylase 6
The HDAC6 protein is part of the HDAC family, which are enzymes catalyzing the deacetylation of proteins, which corresponds to the removal of an acetyl group from lysine residues [76] . The 18 HDACs found in mammals are divided into four classes according to their sequence homology. For classes I (HDAC1, 2, 3, and 8), IIa (HDAC4, 5, 7, and 9), IIb (HDAC6 and 10), and IV (HDAC11), the deacetylation of lysine occurs through a transfer of charge, and their essential component is a zinc ion (Zn 2+ ) present at the bottom of the catalytic pocket of HDAC enzymes [77] . For class III [sirtuins (SIRT) 1-7] HDACs, the presence of a cofactor, nicotinamide adenine dinucleotide (NAD + ), is essential for the reaction [78, 79] .
Class I HDACs are ubiquitously present in many human cell lines and tissues, while class II HDACs exhibit a specific expression profile in certain human tissues such as the heart (HDAC5), the breast (HDAC6), the ovary (HDAC7 and 9), and the kidney (HDAC10) [80, 81] .
Structure
Here, we will focus more specifically on HDAC6 belonging to class IIb. This enzyme is the only HDAC to possess two functional active catalytic sites, and has a nuclear localization sequence, a nuclear export sequence, and a repetitive region of eight consecutive serine-glutamic acid tetradecapeptides, a cytoplasmic retention signal, and is mainly present in the cytoplasm [82] . HDAC6 also has a C-terminal ubiquitin-binding domain required when binding to poly-ubiquitinated proteins (Figure 4 ). 
Function
The HDAC6 protein deacetylates many substrates [83] (Table 4) including -tubulin, cortactin, and heat shock protein (HSP)90, and is thus involved in many cell processes, some of which are described below [84] . The HDAC6 protein plays an important role in the dynamism of two components of the cytoskeleton, actin filaments (or F-actin) and microtubules, -and β-tubulin polymers, which are involved in particular in cell mobility and division. Cortactin, which improves the polymerization of actin filaments, and -tubulin, a constituent of microtubules, are substrates of HDAC6. The deacetylation of cortactin by HDAC6 and SIRT1 leads to its binding to F-actin, improving its polymerization, and thus contributing to cytoskeletal dynamics ( Figure 5A ). The deacetylation of -tubulin by HDAC6 and SIRT2 is associated with microtubule depolymerization, thus contributing to the dynamism of microtubules ( Figure 5B ), and to proteasome-independent protein degradation. When the proteasome is degraded, the polyubiquitinated misfolded proteins are transported to the microtubule-organizing center and are supported by HDAC6 via its ubiquitin binding domain, leading to the formation of aggresomes through deacetylation of cortactin. The aggresomes thus formed are subsequently removed after autophagosome fusion with lysosomes via autophagy ( Figure 5C ). A decrease in the acetylation of microtubule-associated protein 1 light chain 3 by HDAC6 was observed during autophagic degradation [68, 102] . The HDAC6 protein is also involved in proteasome-dependent protein degradation via its interaction with HSP90, a chaperone that stabilizes other proteins when deacetylated by HDAC6. In its acetylated form, HSP90 loses its chaperone function, which leads to the degradation of its client proteins by the proteasome ( Figure  5D ). An accumulation of misfolded proteins causes dissociation of the complex containing HSP90, heat shock factor 1 (HSF) 1, chaperone valosin-containing protein/ATPase, and HDAC6. In complex in inactive form, during dissociation, the release of HSF1 induces the transcription of many HSPs ( Figure 5E ), and HDAC6 will allow its binding to misfolded proteins [68] .
HDAC6 is also involved in apoptosis by deacetylating the Ku70 protein, which then forms a complex with BAX, a proapoptotic protein, allowing the inhibition of apoptosis ( Figure 5F) . Similarly, inhibition of the catalytic activity of HDAC6 promotes the dephosphorylation of AKT and ERK, associated with decreased cell proliferation and death of cancer cells [68] .
Furthermore, HDAC6 regulates endocytosis and exocytosis vesicles. When the epidermal growth factor receptor (EGFR) receptor is bound to its ligand, it interacts with HDAC6 and inactivates it by phosphorylation, which then leads to the hyperacetylation of microtubules and finally the internalization of the receptor. The inhibition of HDAC6 induces the increase of the acetylation of peroxiredoxins 1 and 2, which are antioxidant enzymes, increasing their activity and causing a reduction in cell resistance to chemotherapy [68] . HDAC6 is involved in the process of autophosphorylation of tau protein, giving it the ability to form aggregates called neurofibrillary tangles that can cause neurotoxicity [103] . Figure 5 . The HDAC6 protein is involved in many cellular processes. HDAC6 is involved in F-actin polymerization, microtubule dynamics, anti-apoptotic activity, proteasome-dependent and -independent degradation, transcriptional activation of chaperone proteins, and autophagy. Ac: acetylated; HAT: histone acetyltransferase; HDAC: histone deacetylase; HSF: heat shock factor; HSP: heat shock protein; MTOC: microtubule organizing center; SIRT: sirtuin; VCP: valosin-containing protein/ATPase.
Post-Transcriptional Regulation
There is a lack of current data explaining the post-transcriptional regulation of HDAC6 protein. Nevertheless, some microRNAs stimulating cancer cell proliferation and metastasis formation (miR-22, miR-221, miR-433, and miR-548) [84] , and stem cell differentiation (miR-26a) [104] , are predicted to interact with HDAC6 protein, thus inducing a destabilization or repression of the translation of its mRNA.
Post-Translational Regulation
Post-translational modifications such as phosphorylation and acetylation have a significant impact on HDAC6 functions. Indeed, although EGFR induces an inhibitory phosphorylation of HDAC6, in the majority of cases it is established that the phosphorylation of HDAC6 improves its deacetylase activity, whereas acetylation decreases its enzymatic activity, preventing the deacetylation of -tubulin. Examples of post-translational modifications of the HDAC6 protein influencing its activity are shown in Table 5 . CK2: casein kinase 2; EGFR: epidermal growth factor receptor; ERK1: extracellular signal-regulated kinase; GRK2:
G protein-coupled receptor kinase 2; GSK3: glycogen synthase kinase 3; Lys: lysine; ND: non determined; PKC:
protein kinase C isoform ; Ser: serine; Thr: threonine.
In addition to these known post-translational modifications, there are proteins interacting directly with the HDAC6 protein and inducing its inhibition by direct interaction (Table 6 ). 
HDAC6 Inhibitors
HDAC6 is overexpressed in many types of cancer (Table 7) and may be implicated in disease progression. Peripheral T-cell lymphoma
Overexpressed [118] CD: cluster of differentiation; HDAC6: histone deacetylase 6.
The ability to specifically target HDAC6 would have valuable clinical utility in the treatment of these cancers. However, despite a large number of pan-HDAC inhibitors, very few compounds are capable of selectively inhibiting HDAC6 (Table 8 ). This type of inhibitor can be divided into 2 groups according to their chemical structure: benzamides and hydroxamates [68] . The compounds ACY-241 (Citarinostat) and ACY-1215 (Ricolinostat) are derivatives of hydroxamic acid, which shows a specific inhibitory activity against HDAC6 with IC50 values of 2.6 and 5 nM, respectively. They are the only HDAC6 inhibitors in currently clinical trials (Table 9 ) [130, 160] . To date, no HDAC6 inhibitor has yet been approved by the FDA, unlike pan HDAC inhibitors such as romidepsin, SAHA, PXD101, and LBH589 [173] . Table 9 . HDAC6 Inhibitors in Clinical Trials in Cancer. Clinical studies include four phases. Phase I is performed on healthy volunteers to determine the maximum tolerated dose in humans. Phase II is performed on a limited patient population to determine the optimal dosage. Phase III is performed on several thousand patients and will demonstrate the therapeutic value of the drug and assess its benefit/risk. Phase IV is performed once the drug is marketed and allows to better characterize its adverse effects. It is important to note that inactivation of HDAC6 protein in mice does not result in abnormal development or major organ problems [166] , suggesting that HDAC6 inhibition would have few side effects, unlike pan-HDAC inhibitors.
HDAC6 Inhibitor
Clinical Trial Identification
Phase of the Clinical Trial Pathology
HDAC6 in CML
Several studies have demonstrated the influence of HDAC6 in neurodegenerative, cardiovascular and renal diseases, as well as in inflammation [174] and viral response [84] . The role of the HDAC6 protein in cancer is also now well better understood. Although its oncogenic or tumor suppressor potential is dependent on the type of cancer [68] , its involvement in oncogenic cell transformation, tumor development, and cancer immunity regulation makes a strong therapeutic candidate [113] . The overexpression of HDAC6 in many cancer types led researchers to test the effects of HDAC6 inhibitors on these cancers. Despite the observation of a moderate overexpression of the HDAC6 protein in urothelial cancerous tissues, the inhibition of the protein had limited efficacy compared to the use of inhibitors targeting several HDACs [175] . On the other hand, HDAC6 inhibitors have notable anti-cancer properties in prostate cancer [136] , breast cancer [176] , melanoma [138] , and ovarian cancer [102] . These effects could be explained by the implication of HDAC6 in metastasis formation by epithelial-mesenchymal transition induction via its recruitment by TGF [177] , in cell migration via -tubulin deacetylation and in angiogenesis via cortactin deacetylation [178] . In contrast to some selective HDAC6 inhibitors, currently approved pan-HDAC inhibitors failed to show any clinical benefits in solid tumors [166] . The reasons of such therapeutic failures, compared to the treatment of leukemia and lymphoma, are not fully understood; however, some hypotheses have been raised. For example, the hypothesis of some researchers is based on the cellular composition of solid tumors, which tend to arise from more differentiated cells with reduced epigenetic reprogramming capacity [179] . In addition, solid tumor complexity including genomic, epigenomic, and phenotypical changes, can be a part of the explanation [180] . Moreover, the lack of response of solid tumors treated with HDAC inhibitors could be due to the pharmacokinetic profile of those drugs, which generally have a short half-life [181] . For such reasons, some researchers are investigating new methods and routes of administration of these inhibitors. Accordingly, Wang et al. have demonstrated that the use of nanoparticles to administrate HDAC inhibitors allowing a slow release of the drug directly in solid tumors could induce a higher therapeutic efficacy than classic administration routes [182] .
Similar to pan-HDAC inhibitors approved for the treatment of hematological cancers, specific HDAC6 inhibitors showed anti-cancer properties in various cancer types such as multiple myeloma [183] , chronic lymphocytic leukemia [114] , and acute myeloid leukemia [184] . Here, we will focus on the involvement of HDAC6 in CML.
Nuclear HDAC6 and Its Implication in Leukemia
The cytoplasmic localization of HDAC6 is well described. In leukemia cells, a significant amount of nuclear HDAC6 was revealed, considering the interaction between the nuclear localization sequence (NLS) of HDAC6 and importin-, which translocates HDAC6 into the nucleus. This region can be heavily acetylated resulting in a reduction of the NLS-importin- interaction [185] . Consequently, the presence of HDAC6 in the nucleus of leukemia cells could be explained by red levels of acetylation within the NLS region, compared to other cell types. After nuclear translocation, HDAC6 interacts with nuclear proteins, transcriptional repressors, and transcription factors to regulate gene expression. For example, HDAC6 inhibition has been linked to increased expression of the pro-apoptotic protein BIM in acute myeloid leukemia cells [186] . Moreover, in a model exhibiting significant nuclear HDAC6 levels, chemical HDAC6 inhibition reduces its nuclear localization and p53-HDAC6 interactions inducing cell cycle arrest and apoptosis via changes of p53 target gene expression [187] . The specific nuclear localization of HDAC6 in leukemia cells might offer a therapeutic advantage to specifically target those cells.
Degradation of BCR-ABL via Deacetylation of HSP90α by HDAC6 in the Cytoplasm
Although little research exists on HDAC6 in the context of CML, this protein has a function that makes it particularly interesting in the context of such pathology. HDAC6 deacetylates HSP90, which is involved in the stabilization BCR-ABL [186] . In the acetylated form, HSP90 loses its chaperone function, which leads to the degradation of its client proteins by the proteasome ( Figure  6A ). The importance of the acetylation status of HSP90 in the protein degradation of BCR-ABL makes HDAC6 inhibitors potentially promising molecules for the treatment of CML. Pan-HDAC inhibitors are capable of inducing the inhibition of HDAC6, as well as the downregulation of HDAC6 using si-RNA, which increases the acetylation of HSP90, and in turn increases the ubiquitination of the BCR-ABL protein, decreasing its expression in K562 cells [188, 189] . Figure 6 . Role of HDAC6 in chronic myeloid leukemia. (A) HDAC6 is implicated in proteasome-dependent protein degradation by its interaction with HSP90, a chaperone protein which, when deacetylated by HDAC6, is involved in the stabilization of BCR-ABL. In its acetylated (Ac) form, HSP90 loses its chaperone function, which leads to ubiquitination (Ub) and subsequent degradation of BCR-ABL by the proteasome. (B) Imatinib-insensitive chronic myeloid leukemia (CML) leukemic stem cells (LSCs) overexpress HDAC6 compared to CML cells.
OverExpression of HDAC6 in CML Stem Cells
LSCs that are not targeted by TKI and are characterized by a capacity for self-renewal play a crucial role in CML relapse. Although HDAC6 is necessary for the repression of genes involved in the differentiation targeted by the Tip60-p400 complex in embryonic stem cells (ESCs) [190] , no study has provided evidence for this in LSCs, more differentiated. In contrast, studies have shown that several proteins in the HDAC family are overexpressed in LCSs of CML. Indeed, SIRT1 is activated by BCR-ABL via STAT5 and its expression is increased in LSCs compared to in CML cells [191] . Finally, overexpression of isoforms of HDAC (HDAC1, HDAC2, HDAC3, HDAC4, and HDAC5) and in particular HDAC6 was more frequently observed in LSCs (CD34 + CD38 -) isolated from patients with CML than in K562 cells [117] (Figure 6B ), making it a protein of interest in the search for treatments to prevent relapse in patients with CML.
Conclusions
Despite the success of imatinib and TKIs, the emergence of resistance and the presence of LSCs that are unaffected by these treatments and are responsible for relapse mean that the development of new treatments for CML remains urgent. HDACs represent potential therapeutic targets for the treatment of CML [188, 189, 192] . Inhibitors of the HDAC family have promising results in combination with TKIs [193] , some of which also inhibit HDAC6 [194] [195] [196] . The combination of HDAC class I inhibitors [197] or HDAC inhibitors including HDAC6 [198] and TKIs induces elimination of the quiescent LSCs that are not eradicated during treatment with imatinib alone. Although a decrease in HDAC6 expression, an increase in HSP90 acetylation, and a decrease in BCR-ABL expression were observed in imatinib-resistant K562 cells, these cells still showed sensitivity to SAHA, an inhibitor of HDACs including HDAC6 [186] . However, the high toxicity of HDAC inhibitors and their many side effects [183] has necessitated targeting of particular HDAC isoforms.
The targeting of HDAC6 appears promising because it is overexpressed in many types of cancers, including certain leukemia subtypes. A recent study showed that dasatinib inhibits the phosphorylation of BCR-ABL without inducing the death of LSCs, suggesting that LSCs use signaling pathways that are activated by the BCR-ABL protein and are independent of its tyrosine kinase activity. The simple inhibition of the tyrosine kinase activity of the BCR-ABL protein is therefore not sufficient [199] . Since HDAC6 is overexpressed in CML stem cells and that its inhibition can potentially cause BCR-ABL degradation [68] , this deacetylase appears as a strong candidate for CML treatment. Accordingly, HDAC6 inhibitors could be further tested in combination with TKIs or other molecules capable of targeting BCR-ABL such as bafetinib, rebastinib, tozasertib, danusertib, HG-7-85-01, GNF-2, and -5 molecules, and 1, 3, 4 thiadiazole derivatives, to potentially reduce resistance to treatment [200] . In the future, further development of selective PROTAC E3 ubiquitin ligase degraders triggering HDAC6 degradation [201] will provide further therapeutic options against various types of cancer, including CML.
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